Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06294990

Klinefelter Syndrome and Testosterone Treatment in Puberty

The goal of this randomized clinical trial is to study the effect of testosterone replacement therapy during puberty in boys with Klinefelter syndrome (KS, 47,XXY).

The main questions to answer are how treatment with testosterone will affect body fat mass, lipid and glucose metabolism, growth and body proportions, bone mineralization as well as effects on neurocognitive development and emotional and social difficulties.

Participants will be randomized to two years treatment with testosterone or placebo.

Recruiting

Interested in participating?

Request Info

Key information

About this study

Klinefelter syndrome (KS, 47,XXY) is the most frequent sex chromosome disorder with a prevalence of 1:660 boys. Patients with KS are hypogonadal due to a progressive testicular destruction starting already in childhood. Consequently, the adult male with KS is characterized by small testes, signs of incomplete virilization (e.g. lack of voice deepening, sparse face and body hair, gynecomastia, low muscle mass, reduced penile length), hypergonadotropic hypogonadism, infertility and increased risk of metabolic syndrome, diabetes, cardiovascular disease, osteoporosis and psychosocial and neurodevelopmental challenges. Adults with KS have a poor health and a prevention of the major co-morbidities associated with KS and thereby an improvement in the general health would have an enormous impact on the life of a large cohort of males worldwide.

Sufficient testosterone is not only important in the adult but also during puberty and adolescence for a normal virilization and to improve body composition and body proportions, as well as to maximize peak bone mass acquisition. It has therefore been internationally accepted and makes biological sense to consider testosterone replacement therapy (TRT) during puberty in KS. However, there are no evidence based recommendations, and during recent years TRT in puberty has been questioned and is no longer recommended in some countries. There is a need on an international level for evaluating the effect of this treatment. We therefore aim at evaluating the effect of 2 years TRT during early puberty in boys with KS aged 10 to 14 years in this national, multi-center, randomized, double-blind, placebo-controlled intervention study. The primary endpoint is to evaluate the effect on body fat mass. The secondary endpoints are to evaluate effects on lipid and glucose metabolism, growth and body proportions, bone mineralization as well as effects on neurocognitive development and emotional and social difficulties.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 47,XXY Klinefelter syndrome
  • Age 10-14 years at inclusion
  • Luteinizing Hormone > +2 standard deviations (SD) by ultrasensitive luteinizing hormone assay
  • Free Testosterone<+2 standard deviations
  • Signed consent from parents

Exclusion criteria

  • Previous or ongoing T treatment except for TRT because of micropenis
  • Contraindications to testosterone treatment known hypersensitivity to testosterone or to any other constituent of the gel known or suspected prostatic cancer or breast carcinoma
  • Participation in any other clinical trial

Treatment and study plan

Testosterone gel

Drug

Two years treatment with testosterone

Other names: Testosterone

Placebo

Other

Two years treatment with placebo

Other names: Testosterone

Primary outcomes

  1. Changes in body fat mass

    Time frame: Baseline and 1 and two years

    Evaluation of body fat percentage by whole body dual energy x-ray absorptiometry (DEXA) scan

Secondary outcomes

  1. Pubertal development and virilization

    Time frame: Every three months for two years

    Tanner genital (G) staging from G1 to G5. G1 is the prepubertal stage and G5 is the fully develloped stage.

  2. Pubertal development and virilization

    Time frame: Every three months for two years

    Tanner pubic hair (PH) staging from PH1 to PH6. PH1 is the prepubertal stage and PH6 is the fully develloped stage.

  3. Pubertal development and virilization

    Time frame: Every three months for two years

    Measurement of voice frequency using the app "Voice Analyst" (Speechtools Ltd.).

  4. Pubertal development and virilization

    Time frame: Every three months for two years

    Evaluation of testicular volume by palpation with orchidometer

  5. Pubertal development and virilization

    Time frame: Every three months for two years

    Presence of gynecomastia (yes/no)

  6. Pubertal development and viriliztion

    Time frame: Every three months for two years

    Measurement of luteinizing hormone (LH) (IU/L) in serum

  7. Pubertal development and viriliztion

    Time frame: Every three months for two years

    Measurement of serum concentration of testosterone (nmol/L)

  8. Pubertal development and viriliztion

    Time frame: Every three months for two years

    Measurement of folliclestimulating hormone (FSH) (IU/L) in serum

  9. Pubertal development and viriliztion

    Time frame: Every three months for two years

    Measurement of serum concentration of estradiol (pmol/L)

  10. Pubertal development and viriliztion

    Time frame: Every three months for two years

    Measurement of serum concentration of inhibin B (ng/L)

  11. Pubertal development and viriliztion

    Time frame: Every three months for two years

    Measurement of serum concentration of anti mullerian hormone (AMH) (pmol/L)

  12. Pubertal development

    Time frame: At base line, and at 1 and 2 years

    Measurement of the concentration of luteinizing hormone (LH) and follicle stimulating hormone (FSH) in the first, fasting, morning voiding. Measured in IU/L.

  13. Anthropometry

    Time frame: Every three months for two years

    Measurement of height (cm)

  14. Anthropometry

    Time frame: Every three months for two years

    Measurement of weight (kg)

  15. Anthropometry

    Time frame: Every three months for two years

    Measurement of sitting height (cm)

  16. Anthropometry

    Time frame: At base line, and at 1 and 2 years

    Measurement of head circumference (cm)

  17. Anthropometry

    Time frame: At base line, and at 1 and 2 years

    Measurement of arm span (cm)

  18. Bone health

    Time frame: At baseline and at 1 and two years

    Measurement of whole body bone mineral content (BMC) evaluated by whole body DXA scan

  19. Bone health

    Time frame: At base line, and at 1 and 2 years

    Evaluation of bone health index (BHI) from X-ray of left hand and evaluated using the software BoneXpert version 3 (Hørsholm, Denmark)

  20. Measurement of bone turnover markers

    Time frame: At base line, and at 1 and 2 years

    Measurement of 25-OH-vitamin D in blood sample

  21. Measurement of bone turnover markers

    Time frame: At base line, and at 1 and 2 years

    Measurement of calcium in blood sample

  22. Measurement of bone turnover markers

    Time frame: At base line, and at 1 and 2 years

    Measurement of phosphate in blood sample

  23. Measurement of bone turnover markers

    Time frame: At base line, and at 1 and 2 years

    Measurement of parathyroid hormone (PTH) in blood sample

  24. Measurement of bone turnover markers

    Time frame: At base line, and at 1 and 2 years

    Measurement of carboxy terminal telopeptide of collagen type I (CTX) in blood sample

  25. Measurement of bone turnover markers

    Time frame: At base line, and at 1 and 2 years

    Measurement of alkaline phosphatase in blood sample

  26. Measurement of bone turnover markers

    Time frame: At base line, and at 1 and 2 years

    Measurement of osteocalcin in blood sample

  27. Measurement of bone turnover markers

    Time frame: At base line, and at 1 and 2 years

    Measurement of procollagen type I N-terminal peptide (PINP) in blood sample

  28. Changes in growth

    Time frame: Base line and at 1 and 2 years

    Evaluation of bone age by X-ray of left hand and evaluated using the software BoneXpert version 3 (Hørsholm, Denmark)

  29. Measurement of serum concentrations of growth factors

    Time frame: At base line, and at 1 and 2 years

    Measurement of IGF1, IGF2, IGF1BP-1-6 and acid-labile subunit (ALS)) (microg/L)

  30. Muscle strength

    Time frame: Every three months for two years

    Measurement of standing jump length (cm)

  31. Muscle strength

    Time frame: Every three months for two years

    Measurement of hand grip strength using a digital hand dynamometer (Baseline BIMS, digital hand dynamometer, functional model)

  32. Changes i QTc

    Time frame: Base line and at 1 and 2 years

    Evaluation of QT Interval with electrocardiogram (ECG)

  33. Changes in markers of lipids

    Time frame: Base line and at 1 and 2 years

    Measurement of cholesterol in blood sample

  34. Changes in markers of metabolism

    Time frame: Base line and at 1 and 2 years

    Measurement of adiponectin in blood sample

  35. Changes in markers of metabolism

    Time frame: Base line and at 1 and 2 years

    Measurement of leptin in blood sample

  36. Changes in markers of metabolism

    Time frame: Base line and at 1 and 2 years

    Measurement of glucose in blood sample

  37. Changes in markers of metabolism

    Time frame: Base line and at 1 and 2 years

    Measurement of insulin in blood sample

  38. Changes in markers of metabolism

    Time frame: Base line and at 1 and 2 years

    Measurement of HbA1C in blood sample

  39. Changes in markers of inflammation

    Time frame: Base line and at 1 and 2 years

    Measurement of CRP in blood sample

  40. Neuropsychological evaluation

    Time frame: Baseline and after two years

    The Weschler Intelligence Scale for Children - Fifth Edition (WISC-V). The result is based on a combination of seperate index scores. A higher score generally indicates stronger cognitive abilities.

  41. Neuropsychological evaluation

    Time frame: Baseline and after two years

    The Test of Variables of Attention, version 9 (T.O.V.A) is a computerized, performance-based assessment tool used to measure attention and impulsivity. The result is based on a combination of scores.

  42. Neuropsychological evaluation

    Time frame: Baseline and after two years

    The Test of Memory and Learning, Second Edition (Tomal-2). The results are presented as standard scores, scaled scores, percentile ranks, and index scores. A higher score is a better outcome.

  43. Neuropsychological evaluation

    Time frame: Baseline and after two years

    The Judgement of Line Orientation Test. The result is based on a combination of scores. Higher scores indicate better visual-spatial judgment.

  44. Neuropsychological evaluation

    Time frame: Baseline and after two years

    The Mental Rotation Test

  45. Neuropsychological evaluation

    Time frame: Baseline and after two years

    The Beery-Buktenica Developmental Test of Visual-Motor Integration

  46. Neuropsychological evaluation

    Time frame: Baseline and after two years

    The Baseline Speed subtask of the Amsterdam Neuropsychological Tasks program (ANT)

  47. Neuropsychological evaluation

    Time frame: Baseline and after two years

    The Children's Communication Checklist (CCC-2). The result is evaluated based on 10 subscores. Higher scores indicate stronger communication skills.

  48. Neuropsychological evaluation

    Time frame: Baseline and after two years

    The Social Responsiveness Scale-2 (SRS-2) is a standardized questionnaire used to assess social behavior and autism-related traits. Higher scores indicate greater social difficulties, while lower scores suggest stronger social skills.

  49. Neuropsychological evaluation

    Time frame: Baseline and after two years

    The Delis-Kaplan Executive Function System (D-KEFS). Higher scores indicate better executive functioning, while lower scores may suggest difficulties with problem-solving, impulse control, or flexibility.

  50. Neuropsychological evaluation

    Time frame: Baseline and after two years

    The Behavior Rating Inventory of Executive Function, Second Edition rating scale , parent version (BRIEF-2) assesses executive functioning. The result is based on a combination of scores. Higher scores indicate greater executive function difficulties.

  51. Neuropsychological evaluation

    Time frame: Baseline and after two years

    Behavior Assessment System for Children, Third Edition (BASC-3), parent and self-report version. The result is based on a combination of scores. A higher score indicates more difficulties.

  52. Neuropsychological evaluation

    Time frame: Baseline and after two years

    Self-report version of The Multidimensional Anxiety Scale for Children - 2nd edition (MASC-2). The result is based on a combination of scores. Higher scores suggest greater levels of anxiety and more severe symptoms.

  53. Neuropsychological evaluation

    Time frame: Baseline and after two years

    The parent version of the ADHD-rating scale. The result is based on a combination of scores. Higher scores on the inattention and hyperactivity/impulsivity subscales suggest more significant ADHD symptoms.

  54. Neuropsychological evaluation

    Time frame: Baseline and after two years

    The Adaptive Behavior Assessment System, Third Edition (ABAS-III) is a comprehensive tool used to assess adaptive functioning. The result is based on a combination of scores. A higher score indicates better adaptive functioning.

  55. Neuropsychological evaluation

    Time frame: Baseline and after two years

    The Beck Youth Self-Concept Inventory is a tool designed to assess self-concept and self-esteem in children and adolescents. A high percentile rank (above 70) indicates a strong self-concept, while a low percentile rank (below 30) suggests low self-esteem or dissatisfaction.

  56. Neuropsychological evaluation

    Time frame: Baseline and after two years

    PedsQL Multidimentional Fatigue Scale, parent, and self-report versions is a tool designed to assess fatigue levels in children and adolescents. The result is based on a combination of scores. A higher score indicates less fatigue (better energy levels and functioning). A lower score indicates more fatigue, suggesting that fatigue is significantly affecting the child's daily activities.

  57. Cryopreservation of spermatozoa

    Time frame: After 2 years

    If the patient is able and willing he will have the possibility to deliver a semen sample for cryopreservation of potential spermatozoa

  58. Epigenetic

    Time frame: At base line, and at 1 and 2 years

    The effects on epigenetics will be evaluation by evaluating changes in DNA methylation patterns. This will be analyzed on DNA from white blood cells by applying Illumina methylation arrays.

  59. Genetic effects

    Time frame: At base line, and at 1 and 2 years

    DNA will be analyzed using a selected set of genetic polymorphisms in target genes with established or theoretic effects on hormone production and hormone receptor sensitivity. They will be analysed either by PCR genotyping or targeted sequencing (max. 200 selected genes). SNP arrays that exclusively target common variants, and not any rare variants, will be used to determine the influence of common genetic variation on the observed associations.

  60. Small non-coding RNA

    Time frame: At base line, and at 1 and 2 years

    RNA analysis of circulating, small, non-coding RNA will be performed as a biomarker for the circulating concentrations of reproductive hormones and for overweight.

Study contacts

Contact information is provided by the study sponsor or research team.

Lise Aksglaede, MD

CONTACT

[email protected]

+45 35455064

Sponsors and collaborators

Lead sponsor

Lise Aksglæde

Other

Registry information

Official study title

Klinefelter Syndrome - the Effect of Testosterone Treatment in Puberty. a Randomized, Double-blind Placebo-controlled Intervention Study: 'The TiPY Study'

Acronym: TiPY

Important dates

Study start
2024
Primary completion
2029
Study completion
2029
First posted
Mar 6, 2024
Registry last updated
Feb 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.